Huntington’s disease (HD) is a fatal brain disorder caused by a defect in the huntingtin (HTT) gene, which produces an extra-long protein. This defect causes the HTT protein to form harmful clumps, or ...

9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical ...

5 min read |The Huntington’s disease community’s unprecedented mobilization helped secure a high-priority FDA meeting to discuss the path forward for AMT-130.

Skyhawk Therapeutics has announced results from a Phase 1 clinical study of its experimental huntingtin-lowering drug, SKY-0515. As with all Phase 1 studies, the main goal was to understand safety and ...

Sleep problems are nearly universal in Huntington’s disease (HD) with up to 90% of people with HD reporting sleep-related issues. But new research from a Spanish team suggests these nighttime ...

If you’ve tried to follow Huntington’s disease (HD) clinical trials recently, you’ll know the feeling: so many trials, so many acronyms, and so many announcements. It’s a fantastic problem to have!

UniQure announced on January 9, 2026 that they have scheduled a Type A meeting with the FDA to discuss the approval pathway for AMT-130 in the United States. Type A meetings are urgent, high-priority ...

Doctors have been prescribing drugs to help manage Huntington’s disease (HD) symptoms like chorea (involuntary movements) and irritability for decades. But surprisingly, there are not many studies ...

A recent article in the scientific journal, Nature describes “A natural experiment on the effect of herpes zoster (shingles) vaccination on dementia”. This study makes similar conclusions to other ...